

REMARKS

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

Examination of this application and early allowance are respectfully requested.

Respectfully submitted,



Diane Tso  
Attorney for Applicants  
Reg. No. 46,012

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6807

Date: August 1, 2001

00000159.000101

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the specification:**

The first line of text (title) on page 1 has been amended as follows:

-- SOLID ORAL DOSAGE FORMS OF VALSEARTAN --

The third paragraph on page 6 has been amended as follows:

Thus, where accelerated release is desired, e.g. about 90% release within a ten minute, more particularly a five minute period, a disintegrant such as crosslinked polyvinyl pyrrolidone, for example those products known under the registered trade marks Polyplasdone®XL or Kollidon®CL, in particular having a molecular weight in excess of 1 000 000, more particularly having a particle size distribution of less than 400 microns or less than 74 microns, or reactive additives (effervescent mixtures) that effect rapid disintegration of the tablet in the presence of water, for example so-called effervescent tablets that contain an acid in solid form, typically citric acid, which acts in water on a base containing chemically combined carbon dioxide, for example sodium hydrogencarbonate or sodium carbonate, and releases carbon dioxide could be used.

**In the claims:**

Claims 1-27 have been canceled.

New claims 28-41 have been added.